Evidence supporting the use of hypofractionated PT re-RT remains limited but encouraging, and identifying predictors of toxicity and treatment response is essential to guide future research and to establish this approach as a viable option for selected patients.
D. Alterio, V. Pierini, S. Volpe et al.· International Journal of Par...· 0 citations
Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.
F. Ligorio, L. Provenzano, R. Caputo et al.· EClinicalMedicine· 0 citations
BACKGROUND AND PURPOSE
The treatment landscape for breast cancer has undergone significant advancements in the recent years, with the introduction of several new anticancer agents, especially those belonging to the antibody-drug conjugates (ADCs) class. However, there exists a lack of comprehensive evidence regarding t...
L. Visani, C. Becherini, M. Kubeczko et al.· Radiotherapy and Oncology· 0 citations